December 2016
-
Aerogen has licensed its OnQ nebulizer technology to a San Francisco, California company, Dance Pharmaceuticals for development of a new inhaled insulin solution product. Dance founder John S. Patton was a co-founder of Inhale Therapeutics,… Read more . . .
-
According to a new report by the National Center for Health Statistics of the US Center for Disease Control (CDC), the 2009 US asthma rate rose to 8.2% of the population, a historic high. The… Read more . . .
-
Civitas Therapeutics has obtained $20 million in Series A financing for development of its lead product, a DPI intended for the treatment of Parkinson’s disease. The assets Civitas has licensed from Alkermes include a pipeline,… Read more . . .
-
With the addition of new Harro Höfliger Omnidose filling equipment at its Research Triangle Park facility, Catalent now has the ability to provide DPI filling from clinical manufacturing through commercial manufacturing, according to the company.… Read more . . .
-
Almirall and Forest Laboratories have announced that Phase 3 studies of inhaled aclidinium and Phase 2b studies of an inhaled aclidinium/formoterol combination both met their primary endpoints. As a result, the companies expect to submit… Read more . . .
-
Contract manufacturer Ritedose has voluntarily recalled unit dose vials of albuterol inhalation solution due to mislabeling. The single dose vials contain a 2.5 mg/3 mL solution but are labeled as 0.5 mg/3 mL. The product… Read more . . .
-
A subsidiary of Footstar has entered into an agreement to acquire New Hampshire specialty pharma company CPEX, which is developing Nasulin intranasal insulin spray. Nasulin is in Phase 2 development, and CPEX has been seeking… Read more . . .
-
The results from Inspire Pharmaceuticals’ second Phase 3 trial of denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis show that the drug failed to meet its primary endpoint, change in FEV from baseline.… Read more . . .
-
According to Mannkind Corporation, the FDA has informed the company that it will need another four weeks or so before it issues a decision on the NDA for Afrezza inhaled insulin. The original action date… Read more . . .
-
Belgian pharma equipment manufacturer Procept and Spanish tech company Ingeniatrics Tecnologías have signed an agreement to develop a new spray drying system based on Ingeniatrics’ Flow Focusing technology, which is a "microfluidic technology capable of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland